Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO
Glaxosmithkline Pharmaceuticals — Investor Presentation (August 2022)
22 slides from Glaxosmithkline Pharmaceuticals's investor presentation, Aug 24, 2022
Slide 1: Presentation for Analyst Meet (exchange filing cover letter)
Sate GSK GlaxoSmithKline Pharmaceuticals Limited, GSK House, Dr. Annie Besant Road, Worli Mumbai - 400 030 (India) T49) 22 2495 9595 F +91 22 2495 9494 August 24, 2022 To, BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA Phiroze Jeejeebhoy Towers Exchange Plaza, 5" Floor, Plot No. C/1, G Block Dalal
Slide 2: Analyst Meet 23rd August 2022
gsk.com Analyst Meet 23rd August 2022
Slide 3: Agenda
Agenda Welcome GSK India Overview Financial Overview Awards and Recognitions for GSK India Q&A
Slide 4: Sridhar Venkatesh, Vice President, South Asia & Managing Director
Sridhar Venkatesh, Vice President, South Asia & Managing Director 11 Years in GSK, Leadership roles across countries Mr. Sridhar Venkatesh is a senior business leader with more than 24 years of diverse experience in pharmaceuticals & healthcare and has a strong track record of success in multiple ro
Slide 5: Juby Chandy, CFO- GSK Pharma, India
Juby Chandy, CFO- GSK Pharma, India 14 Years in GSK (from 2007), International experience in 5 countries Mr. Juby Chandy is an experienced Finance Leader who has worked at the regional and country levels for GSK in several countries. He has been with the GSK group for over 14 years, holding increasi
Slide 6: Our purpose
Our purpose We unite science, technology and talent to get ahead of disease together 23 August 2022 5
Slide 7: For health impact + shareholder returns + thriving people
For health impact + shareholder returns + thriving people • We aim to positively impact the health of 2.5 billion people over the next 10 years. • Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. • And to making GSK a company where people c
Slide 8: How we'll get ahead together
How we’ll get ahead together: Our culture and thriving GSK people We’re investing in innovation (Nucala & Ambitious for patients Trelegy & Shingrix) and growth at pace to achieve health impact at scale. We set focused objectives with clear Accountable for impact measures of success. Do the right thi
Slide 9: GSK India continues to be a Relevant Part of Emerging Market (EM)
GSK India continues to be a Relevant Part of Emerging Market (EM) % Contribution EM Sales India 13% 15% 17% 22% 45% Rest of EM 87% Infanrix/Boostrix Augmentin Fluarix Derma GSK India is the 2nd highest contributor to EM Source: Internal India %Share in EM 23 August 2022 8
Slide 10: Driving Sustainable Growth through execution focus & building capabilities for new launches
Driving Sustainable Growth through execution focus & building capabilities for new launches General Medicines • Build on Core Brands | EI >100 • Improve Margins (+ ROI) Vaccines • Drive Pediatric Vx growth in private market • Focus on growth of Adult Vaccination Specialty • Focus on recruiting new p
Slide 11: Maintaining Market Share for key brands
Maintaining Market Share for key brands Key Promoted Brands %Market share 30.4% 30.3% 30.1% 27.4% 2019 2020 2021 YTD 2022 Calendar Year 10
Slide 12: We Continue to Lead in our Represented market
We Continue to Lead in our Represented market Brand Leadership Rx Leadership No #1 in its Represented market Therapy Leadership No #1 in its Augmentin, Calpol, Ceftum, T-Bact, Neosporin, represented market across Betnovates, No #1 in Dermatology, key customers: GP, Pediatrician, Dentist, Infanrix He
Slide 13: Vaccine Consumer campaigns further accelerated driving awareness & need for vaccination
Vaccine Consumer campaigns further accelerated driving awareness & need for vaccination Launched in 12 languages with a clear objective to increase awareness & HCP Consultations “Flu Vaccination Awareness “6 in 1 campaign” campaign” ~2 Mn Visitors in 2022 Reach: 35 Mn,TV & Digital Impressions: >1Bn
Slide 14: Building Specialty
Building Specialty Nucala Trelegy-A Phygital Launch Shingrix ➢ Leading asthma biologic in SEA Shingrix Launch planned for space/ for SEA patients in India first half of 2023 ➢ Approved in major public accounts like Central Government Health Services (CGHS), Employee State Insurance (ESI) etc. 23 Aug
Slide 15: FY2022 Snapshot (Continuing Operations)
FY2022 Snapshot (Continuing Operations) Sales 3,190 cr Gross Margin PBT (before exceptional) 1,894 cr 761 cr Topline + 11% Price Grth : 5%;Volume Grth : 6% @59%, +3%* @24%, +2%* Promoted Brands +25% General Specialty Vaccines Medicines +19% +86% -9% EBITDA Dividend 756 cr 900% • Calpol +100% • Augme
Slide 16: Q1 FY2023 Snapshot (Continuing Operations)
Q1 FY2023 Snapshot (Continuing Operations) Sales 715 cr Underlying + 12% Price Grth ~6%;Volume Grth ~6% General Specialty Vaccines Medicines >100% +9% +12% Gross Margin EBITDA 442 cr 148 cr @62%, +2% @20%, +1% (cyclic nature) 15
Slide 17: FY 2021-22, strong improvement on financials
FY 2021-22 , strong improvement on financials Growing in line with industry trend ▪ Higher Gross Profit from better ▪ GP improvement 1.8% pricing and favourable mix ▪ Lower employee costs from 3,500 ~ + 8% impacts. strategic commercial restructuring 2.2% 3,218 3,000 ▪ Lower opex from cost 2,982 2,92
Slide 18: India Growth Strategy: sustainable growth across continuing portfolios
India Growth Strategy : sustainable growth across continuing portfolios Sales values* (Cr) 5 Year CAGR (continuing portfolio) 3,600 General Medicines 3,400 +9% ( continuing portfolio) 3,200 3,190 3,000 Vaccines 2,800 2,944 2,886 +10% 2,863 2,600 2,632 2,400 Specialty >100% 2,200 2,000 Strong Cashflo
Slide 19: EBITDA Margin improvement and focus further
EBITDA Margin improvement and focus further EBITDA (Cr) and Margins 900 25% Focus areas 800 ▪ Grow our promoted brands 756 to drive profitable growth 20% 700 ▪ WPI backed price 600 555 598 increases to help tide over 513 15% inflation impacts and 500 potential NLEM impacts 421 400 23% ▪ New Product
Slide 20: Awards and Recognitions
Awards and Recognitions GSK Pharma India GSK recognized as conferred the CNBC one of the 100 Best TV18 India Risk Companies for Management Award Women in India in the Pharma sector 2021 by Working Mother and AVTAR. GSK Head Office in Mumbai conferred the ‘Safe Place to Work’ recognition GSK Pharma I
Slide 21: Touching the lives of people everyday for their better health
Touching the lives of people everyday for their better health Each year our General medicines ~6 million immunization sessions by portfolio benefits ̴ 200m patients and GSK vaccines continue to protect more lives 23 August 2022 20
Slide 22: Q&A
Q&A
GlaxoSmithKline Pharmaceuticals — Investor Presentation (August 2022) on 6ix